DDC and Parkinson disease: In the second study, 782 patients with early Parkinson's disease were randomly allocated to approved treatments (levodopa and DOPA decarboxylase inhibitor alone; levodopa, DOPA decarboxylase inhibitor, and selegiline; or bromocriptine).